STAAR Surgical's (STAA) EVO Visian Toric ICL Approved in Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
STAAR Surgical Announces Approval by Health Canada of Its EVO Visian ICL™ Toric Lens Specifically Designed for the Nearsighted Patient with Astigmatism
September 22, 2016 2:40 PM EDTMONROVIA, Calif., Sept. 22, 2016 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, was notified yesterday of the approval of its EVO Visian Toric ICL,  STAAR's Implantable Collamer® Lens, for distribution in Canada by the Medical Devices Bureau of Health Canada. Â
With extensive clinical experience globally, the EVO and EVO Toric ICL is STAAR's next-generation lens implanted in the eye that works with the patient's natural eye to correct vision. Â Over 40% of STAAR's EVO ICL sales globally are... More
